Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antirheumatic Agents | 6 | 2021 | 43 | 1.210 |
Why?
|
| Dermatomyositis | 1 | 2010 | 10 | 0.370 |
Why?
|
| Paraneoplastic Syndromes | 1 | 2010 | 24 | 0.360 |
Why?
|
| Spondylitis, Ankylosing | 1 | 2009 | 11 | 0.350 |
Why?
|
| Skin Diseases, Bacterial | 1 | 2009 | 14 | 0.350 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2009 | 36 | 0.350 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 1 | 2009 | 19 | 0.340 |
Why?
|
| Immunoglobulin G | 1 | 2009 | 227 | 0.330 |
Why?
|
| Immunosuppressive Agents | 1 | 2009 | 248 | 0.300 |
Why?
|
| Methotrexate | 3 | 2021 | 73 | 0.240 |
Why?
|
| Anti-Bacterial Agents | 1 | 2009 | 825 | 0.220 |
Why?
|
| Withholding Treatment | 2 | 2019 | 21 | 0.210 |
Why?
|
| Macrophage Activation Syndrome | 1 | 2020 | 4 | 0.190 |
Why?
|
| Panniculitis | 1 | 2020 | 7 | 0.190 |
Why?
|
| Pulmonary Alveolar Proteinosis | 1 | 2020 | 6 | 0.190 |
Why?
|
| Interleukin-18 | 1 | 2020 | 27 | 0.180 |
Why?
|
| Interferon Type I | 1 | 2020 | 30 | 0.180 |
Why?
|
| Calgranulin B | 1 | 2019 | 6 | 0.170 |
Why?
|
| Calgranulin A | 1 | 2019 | 7 | 0.170 |
Why?
|
| Autoimmune Diseases | 1 | 2020 | 115 | 0.170 |
Why?
|
| Naproxen | 1 | 2018 | 8 | 0.170 |
Why?
|
| Hereditary Autoinflammatory Diseases | 1 | 2018 | 5 | 0.160 |
Why?
|
| Azetidines | 1 | 2018 | 7 | 0.160 |
Why?
|
| Janus Kinase 1 | 1 | 2018 | 20 | 0.160 |
Why?
|
| Janus Kinase 2 | 1 | 2018 | 31 | 0.160 |
Why?
|
| Interferons | 1 | 2018 | 44 | 0.160 |
Why?
|
| Induction Chemotherapy | 1 | 2018 | 59 | 0.160 |
Why?
|
| Child | 8 | 2021 | 7372 | 0.160 |
Why?
|
| Proton Pump Inhibitors | 1 | 2018 | 84 | 0.150 |
Why?
|
| Registries | 1 | 2020 | 552 | 0.150 |
Why?
|
| Adolescent | 7 | 2020 | 6896 | 0.150 |
Why?
|
| Sulfonamides | 1 | 2018 | 146 | 0.150 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2018 | 142 | 0.150 |
Why?
|
| Child, Preschool | 5 | 2020 | 4161 | 0.140 |
Why?
|
| Transcription, Genetic | 1 | 2017 | 418 | 0.140 |
Why?
|
| Inflammation | 1 | 2018 | 679 | 0.120 |
Why?
|
| Drug Therapy, Combination | 3 | 2020 | 426 | 0.120 |
Why?
|
| Mutation | 1 | 2020 | 1504 | 0.110 |
Why?
|
| Treatment Outcome | 5 | 2021 | 5609 | 0.100 |
Why?
|
| Male | 8 | 2020 | 27335 | 0.090 |
Why?
|
| Mycobacterium marinum | 1 | 2009 | 4 | 0.090 |
Why?
|
| Candidiasis, Cutaneous | 1 | 2009 | 5 | 0.090 |
Why?
|
| Opportunistic Infections | 1 | 2009 | 58 | 0.090 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2009 | 119 | 0.080 |
Why?
|
| Humans | 10 | 2021 | 54304 | 0.080 |
Why?
|
| Candida | 1 | 2009 | 67 | 0.080 |
Why?
|
| Immunocompromised Host | 1 | 2009 | 130 | 0.080 |
Why?
|
| Prospective Studies | 3 | 2018 | 2604 | 0.080 |
Why?
|
| Immunotherapy | 1 | 2009 | 264 | 0.070 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2019 | 435 | 0.070 |
Why?
|
| Antifungal Agents | 1 | 2009 | 363 | 0.070 |
Why?
|
| Female | 7 | 2020 | 28457 | 0.070 |
Why?
|
| Skin | 1 | 2009 | 468 | 0.070 |
Why?
|
| Prognosis | 1 | 2010 | 2126 | 0.060 |
Why?
|
| Time Factors | 2 | 2019 | 3207 | 0.050 |
Why?
|
| Uveitis | 1 | 2020 | 28 | 0.050 |
Why?
|
| Infant | 2 | 2018 | 3832 | 0.040 |
Why?
|
| Maintenance Chemotherapy | 1 | 2019 | 48 | 0.040 |
Why?
|
| Life Tables | 1 | 2018 | 8 | 0.040 |
Why?
|
| Compassionate Use Trials | 1 | 2018 | 7 | 0.040 |
Why?
|
| Purines | 1 | 2018 | 45 | 0.040 |
Why?
|
| Pyrazoles | 1 | 2018 | 110 | 0.040 |
Why?
|
| Treatment Failure | 1 | 2017 | 141 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2018 | 430 | 0.040 |
Why?
|
| Cluster Analysis | 1 | 2017 | 244 | 0.040 |
Why?
|
| Sequence Analysis, RNA | 1 | 2017 | 107 | 0.040 |
Why?
|
| Monocytes | 1 | 2017 | 156 | 0.040 |
Why?
|
| Transcriptome | 1 | 2017 | 346 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2017 | 1229 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2017 | 1083 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2018 | 1547 | 0.030 |
Why?
|
| Middle Aged | 1 | 2009 | 13076 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 2389 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2017 | 1141 | 0.030 |
Why?
|
| Risk Factors | 1 | 2018 | 3934 | 0.020 |
Why?
|
| Young Adult | 1 | 2018 | 4313 | 0.020 |
Why?
|
| United States | 1 | 2018 | 5204 | 0.020 |
Why?
|